Serum S100A12 as a new marker for inflammatory bowel disease and its relationship with disease activity

Gut

Volumn 59, Issue 12, 2010, Pages 1728-1729

  Brinar, Marko ^a   Cleynen, Isabelle ^a   Coopmans, Tamara ^a   Van Assche, Gert ^a   Rutgeerts, Paul ^a   Vermeire, Severine ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; INFLIXIMAB; PROTEIN S 100; PROTEIN S100A12; UNCLASSIFIED DRUG;

ADULT; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ULCERATIVE COLITIS;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; S100 PROTEINS;

EID: 78649857801     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.194100     Document Type: Letter

References (3)

1. Foell D, Kucharzik T, Kraft M, et al. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed duroing chronic active inflammatory bowel disease. Gut 2003;52:847-53. (Pubitemid 36613492)
2. Kaiser T, Langhorst J, Wittkowski H, et al. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 2007;56:1706-13. (Pubitemid 350206297)
3. Larsen A, Bronstein IB, Dahl O, et al. Quantification of S100A12(EN-RAGE) in blood varies with sampling method, calcium and heparin. Scand J Immunol 2007;65:192-201.